Simvastatin has been found to reduce ovarian cancer cell adhesion to peritoneal mesothelial cells through decreased expression of VCAM-1 and β1 integrin in vitro [36], suggesting that simvastatin may provide a novel therapeutic approach to the prevention of peritoneal carcinomatosis. Here, VCAM1 is linked to ovarian carcinoma.